Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

The incidence of cutaneous melanoma has continued to increase in recent years. For early-stage melanoma, surgical resection is the standard treatment and is associated with an excellent long-term prognosis, with 5-year survival rates of 98% for stage I disease and 90% for stage II disease. However,…

from Cancer via ola Kala on Inoreader http://ift.tt/2eYhcY8
via IFTTT